BGI Genomics Co., Ltd.

Shenzhen Stock Exchange 300676.SZ

BGI Genomics Co., Ltd. EBT Margin for the year ending December 31, 2023: 2.66%

BGI Genomics Co., Ltd. EBT Margin is 2.66% for the year ending December 31, 2023, a -81.41% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

BGI Genomics Co., Ltd. EBT Margin for the year ending December 31, 2022 was 14.29%, a -44.62% change year over year.
BGI Genomics Co., Ltd. EBT Margin for the year ending December 31, 2021 was 25.80%, a -11.28% change year over year.
BGI Genomics Co., Ltd. EBT Margin for the year ending December 31, 2020 was 29.08%, a 148.18% change year over year.
BGI Genomics Co., Ltd. EBT Margin for the year ending December 31, 2019 was 11.72%, a -37.41% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

Shenzhen Stock Exchange: 300676.SZ

BGI Genomics Co., Ltd.

CEO	Mr. Lijian Zhao
IPO Date	July 14, 2017
Location	China
Headquarters	Building No.7
Employees	3,752
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2. The company offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China.

Key trends

Past 5 years